all report title image
  • To Be Published : Sep 2023
  • Code : CMI1976
  • Pages : N/A
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Hyperphosphatemia is a condition caused due to high level of phosphate or phosphorous in the blood. Phosphate is a chemical found in body and contain mineral called phosphorous. Phosphorus mineral is very important for the development of teeth and bones and also convert food into energy for body.

Phosphate is mainly found in the teeth, bones, inside the cells, and in very smaller amounts in the blood. Kidney functions for the management of phosphate level in the body. However, various complications/diseases results into impairment of kidney, which leads to chronically high level of phosphate in blood.

Hyperphosphatemia is very common in people with chronic kidney disease more often in people with end-stage kidney disease. Some other possible causes of hyperphosphatemia includes diabetic ketoacidosis, uncontrolled diabetes, high vitamin D levels, and low parathyroid hormone levels.

Hyperphosphatemia Drugs Market Drivers

Increasing launches and approval of novel drugs in key regions are expected to fuel the global hyperphosphatemia drugs market growth in near future. For instance, in 2016, Astellas Pharma Inc. received marketing approval for its Kiklin Granules 86.2%, indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease in Japan. In 2015, Keryx Biopharmaceuticals, Inc. received approval from European Commission for new drug Fexeric (R) (ferric citrate coordination complex), indicated for the treatment of hyperphosphatemia in adults with chronic kidney disease.

In 2014, Keryx Biopharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for drug Ferric Citrate (formerly known as Zerenex), a new, oral iron-based treatment for dialysis patients with hyperphosphatemia. In 2014, Keryx Biopharmaceuticals, Inc. launched its new drug Auryxia (ferric citrate) tablets. Auryxia is an absorbable iron-based phosphate binder indicated for the treatment of hyperphosphatemia in chronic kidney disease

Strategic merger and acquisition by key players in the market is also expected to create a lucrative environment for the hyperphosphatemia drugs market growth. For instance, in 2013, OPKO Health, Inc. acquired Canada-based Cytochroma Inc., with this strategic acquisition OPKO Health, Inc. has expanded its portfolio with Cytochroma Inc.’s Alpharen, a non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients.

Furthermore, risk of developing hyperphosphatemia is very high in the people suffering from chronic kidney disease. Hence, increasing prevalence of chronic kidney disease is expected to increase the chances of hyperphosphatemia among population, which in turn is expected to increase demand for hyperphosphatemia drugs and drive hyperphosphatemia drugs market growth.

For instance, according to the data published in National Chronic Kidney Disease Fact Sheet 2017, an estimated 30 million people or 15% of U.S. adults are suffering from chronic kidney disease. Chronic kidney diseases were estimated to be more common in Women (16%) as compared to men (13%).

Hyperphosphatemia Drugs Market Regional Analysis

North America is expected to hold a dominant position in global hyperphosphatemia drugs market and it is expected to account for largest market size, due to presence of key players in region and frequent research and development activities by them for development of novel drugs for treatment of hyperphosphatemia. For instance, in 2017, U.S.-based Ardelyx, Inc. received positive results in Phase 3 clinical trial for new drug Tenapanor. Tenapanor is a first-in-class, proprietary, oral, experimental medication indicated for the treatment of hyperphosphatemia in patients with end-stage renal disease.

Furthermore, Asia Pacific hyperphosphatemia drugs market is expected to witness significant growth in near future owing to increasing approval of novel hyperphosphatemia treatment drug in key regions such as China, and Japan. For instance, in 2014, Japan Tobacco Inc. and its subsidiary Torii Pharmaceutical Co., Ltd. received manufacturing and marketing approval of Riona Tablets 250 mg from Japanese Ministry of Health, Labor and Welfare. Riona tablet is indicated for treatment of hyperphosphatemia, it is a new phosphate binder containing ferric citrate hydrate as the active pharmaceutical ingredient.

Hyperphosphatemia Drugs Market Key Players

Key players operating in global hyperphosphatemia drugs market include: Keryx Biopharmaceuticals, Inc., Astellas Pharma Inc., Japan Tobacco Inc., Ardelyx, Inc., OPKO Health, Inc., BioLink Life Sciences, Inc., F Hoffmann-La Roche AG, Lupin Limited, Fresenius Medical Care, and Vifor Pharma Group.

Hyperphosphatemia Drugs Market Taxonomy:

The global hyperphosphatemia drugs market is segmented on the basis of product type, dosage from, distribution channel, and region

By Product Type-

  • Calcium carbonate
  • Calcium acetate
  • Calcium acetate/Magnesium carbonate
  • Aluminum Hydroxide
  • Sevelamer hydrochloride
  • Sevelamer carbonate
  • Bixalomer
  • Lanthanum Carbonate
  • Sucroferric Oxyhydroxide
  • Ferric Citrate

By Dosage Form-

  • Tablet
  • Capsule
  • Solution/Suspension

By Distribution Channel-

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region-

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount

Reliability and Reputation

DUNS Registered
DMCA Protected


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo